Prevnar-13 now approved for adults 50+

[Guest guest]

I just saw that Prevnar-13 has just received FDA approval for use in adults 50 and older for prevention of pneumococcal pneumonia. This is an alternative to the Pneumovax vaccine. This may be helpful for those of us who have trouble using up all 10 doses of Prevnar-13 because our volume of pediatric patients is low. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm285431.htmBelow is Pfizer's page on Prevnar-13. One noteworthy tidbit: "In adults, antibody responses to Prevnar 13® were diminished when given with inactivated Influenza Virus Vaccine".http://www.pfizerpro.com/hcp/prevnar13-adultI have no financial interests in Prevnar or Pneumovax. SetoSouth Pasadena, CA

[Guest guest]

Maybe. See quotes below from this article:http://www.medpagetoday.com/InfectiousDisease/Vaccines/29755There is currently only one other pneumococcal vaccine for adults -- a free polysaccharide vaccine from Merck called Pneumovax 23 -- but its protection lasts only three to five years and it's unclear whether it's effective at preventing nonbacteremic pneumococcal pneumonia, which is the more common type of pneumococcal disease in adults.If approved, Prevnar 13 would be the first conjugate vaccine approved for adults. It is longer-lasting than the polysaccharide vaccine and triggers a memory response in the immune system that may make it more effective than Pneumovax 23.andOne of those trials randomized 835 adults ages 60 to 64 to receive either a single dose of Prevnar 13 or Pneumovax; those patients had never received a pneumococcal vaccination. The trial also included 400 adults ages 50 to 59 who received Prevnar 13 in an open-label fashion.Antibody levels were measured one month after vaccination. In the older group, Prevnar 13 was at least as immunogenic as Pneumovax 23 for all 12 serotypes common to both vaccines, and induced significantly higher functional antibody levels for eight of the shared serotypes, in addition to serotype 6A.Prevnar 13 was as immunogenic in the younger group as in the older group for all vaccine serotypes. The functional antibody response was significantly higher in the younger group for nine of the 13 serotypes.In another of the phase III studies, researchers randomized 936 adults in the U.S. and Sweden who were 70 and older to one of the two vaccines. All of the participants had been vaccinated with Pneumovax 23 at least five years before the start of the study.The also showed that Prevnar 13 was at least as immunogenic as Pneumovax 23 for all shared serotypes, with a functional antibody response that was significantly greater for 10 of the 12 shared serotypes, as well as for serotype 6A, which Pneumovax does not protect against. SetoSouth Pasadena, CA

And is it any better? Kathy Saradarian, MDBranchville, NJwww.qualityfamilypractice.comSolo 4/03, Practicing since 9/90Practice Partner 5/03Low staffing From: [mailto: ] On Behalf Of SetoSent: Monday, January 30, 2012 1:53 PMTo: Subject: Prevnar-13 now approved for adults 50+ I just saw that Prevnar-13 has just received FDA approval for use in adults 50 and older for prevention of pneumococcal pneumonia. This is an alternative to the Pneumovax vaccine. This may be helpful for those of us who have trouble using up all 10 doses of Prevnar-13 because our volume of pediatric patients is low. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm285431.htm Below is Pfizer's page on Prevnar-13. One noteworthy tidbit: "In adults, antibody responses to Prevnar 13® were diminished when given with

inactivated Influenza Virus Vaccine".http://www.pfizerpro.com/hcp/prevnar13-adult I have no financial interests in Prevnar or Pneumovax. SetoSouth Pasadena, CA

[Guest guest]

I noticed that the prevnar 13 is more expensive than the pneumovax.

I was wondering if we have to buy the prevnar 13 for our small kids ( the 10 package), when I use it in an adult the insurance would pay for the more expensive vaccine.?

I tried to contact a pediatrician office but they were not so willing to sell me the dose that I need.

I noticed that primary care is not to friendly to other primary care in the area.

Adolfo

To: Sent: Monday, January 30, 2012 4:32 PMSubject: Re: Prevnar-13 now approved for adults 50+

Maybe. See quotes below from this article:

http://www.medpagetoday.com/InfectiousDisease/Vaccines/29755

There is currently only one other pneumococcal vaccine for adults -- a free polysaccharide vaccine from Merck called Pneumovax 23 -- but its protection lasts only three to five years and it's unclear whether it's effective at preventing nonbacteremic pneumococcal pneumonia, which is the more common type of pneumococcal disease in adults.

If approved, Prevnar 13 would be the first conjugate vaccine approved for adults. It is longer-lasting than the polysaccharide vaccine and triggers a memory response in the immune system that may make it more effective than Pneumovax 23.

and

One of those trials randomized 835 adults ages 60 to 64 to receive either a single dose of Prevnar 13 or Pneumovax; those patients had never received a pneumococcal vaccination. The trial also included 400 adults ages 50 to 59 who received Prevnar 13 in an open-label fashion.

Antibody levels were measured one month after vaccination. In the older group, Prevnar 13 was at least as immunogenic as Pneumovax 23 for all 12 serotypes common to both vaccines, and induced significantly higher functional antibody levels for eight of the shared serotypes, in addition to serotype 6A.

Prevnar 13 was as immunogenic in the younger group as in the older group for all vaccine serotypes. The functional antibody response was significantly higher in the younger group for nine of the 13 serotypes.

In another of the phase III studies, researchers randomized 936 adults in the U.S. and Sweden who were 70 and older to one of the two vaccines. All of the participants had been vaccinated with Pneumovax 23 at least five years before the start of the study.

The also showed that Prevnar 13 was at least as immunogenic as Pneumovax 23 for all shared serotypes, with a functional antibody response that was significantly greater for 10 of the 12 shared serotypes, as well as for serotype 6A, which Pneumovax does not protect against.

Seto

South Pasadena, CA

And is it any better?

Kathy Saradarian, MD

Branchville, NJ

www.qualityfamilypractice.com

Solo 4/03, Practicing since 9/90

Practice Partner 5/03

Low staffing

From: [mailto: ] On Behalf Of SetoSent: Monday, January 30, 2012 1:53 PMTo: Subject: Prevnar-13 now approved for adults 50+

I just saw that Prevnar-13 has just received FDA approval for use in adults 50 and older for prevention of pneumococcal pneumonia. This is an alternative to the Pneumovax vaccine. This may be helpful for those of us who have trouble using up all 10 doses of Prevnar-13 because our volume of pediatric patients is low.

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm285431.htm

Below is Pfizer's page on Prevnar-13. One noteworthy tidbit: "In adults, antibody responses to Prevnar 13® were diminished when given with inactivated Influenza Virus Vaccine".

http://www.pfizerpro.com/hcp/prevnar13-adult

I have no financial interests in Prevnar or Pneumovax.

Seto

South Pasadena, CA

[Guest guest]

Adolfo,I got MY doctor's office to sell me a few Prevnar when I need them.  It is a bit of a hassle, but I like keeping the babies I get.....  Maybe worth trying another office or two, especially if you are friendly with any.

Sharon

 

I noticed that the prevnar 13 is more expensive than the pneumovax.

I was wondering if we have to buy the prevnar 13 for our small kids ( the 10 package), when I use it in an adult the insurance would pay for  the more expensive vaccine.?

I tried to contact a pediatrician office but they were not so willing to sell me the dose that I need.

I noticed that primary care is not to friendly to other primary care in the area.

Adolfo

To: Sent: Monday, January 30, 2012 4:32 PM

Subject: Re: Prevnar-13 now approved for adults 50+

 

Maybe. See quotes below from this article:

http://www.medpagetoday.com/InfectiousDisease/Vaccines/29755

There is currently only one other pneumococcal vaccine for adults -- a free polysaccharide vaccine from Merck called Pneumovax 23 -- but its protection lasts only three to five years and it's unclear whether it's effective at preventing nonbacteremic pneumococcal pneumonia, which is the more common type of pneumococcal disease in adults.

If approved, Prevnar 13 would be the first conjugate vaccine approved for adults. It is longer-lasting than the polysaccharide vaccine and triggers a memory response in the immune system that may make it more effective than Pneumovax 23.

and

One of those trials randomized 835 adults ages 60 to 64 to receive either a single dose of Prevnar 13 or Pneumovax; those patients had never received a pneumococcal vaccination. The trial also included 400 adults ages 50 to 59 who received Prevnar 13 in an open-label fashion.

Antibody levels were measured one month after vaccination. In the older group, Prevnar 13 was at least as immunogenic as Pneumovax 23 for all 12 serotypes common to both vaccines, and induced significantly higher functional antibody levels for eight of the shared serotypes, in addition to serotype 6A.

Prevnar 13 was as immunogenic in the younger group as in the older group for all vaccine serotypes. The functional antibody response was significantly higher in the younger group for nine of the 13 serotypes.

In another of the phase III studies, researchers randomized 936 adults in the U.S. and Sweden who were 70 and older to one of the two vaccines. All of the participants had been vaccinated with Pneumovax 23 at least five years before the start of the study.

The also showed that Prevnar 13 was at least as immunogenic as Pneumovax 23 for all shared serotypes, with a functional antibody response that was significantly greater for 10 of the 12 shared serotypes, as well as for serotype 6A, which Pneumovax does not protect against.

Seto

South Pasadena, CA

 

And is it any better?

 

 

Kathy Saradarian, MD

Branchville, NJ

www.qualityfamilypractice.com

Solo 4/03, Practicing since 9/90

Practice Partner 5/03

Low staffing

 

 

 

From: [mailto: ] On Behalf Of Seto

Sent: Monday, January 30, 2012 1:53 PMTo: Subject: Prevnar-13 now approved for adults 50+

 

 

I just saw that Prevnar-13 has just received FDA approval for use in adults 50 and older for prevention of pneumococcal pneumonia. This is an alternative to the Pneumovax vaccine. This may be helpful for those of us who have trouble using up all 10 doses of Prevnar-13 because our volume of pediatric patients is low. 

 

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm285431.htm

 

Below is Pfizer's page on Prevnar-13. One noteworthy tidbit: " In adults, antibody responses to Prevnar 13® were diminished when given with inactivated Influenza Virus Vaccine " .

http://www.pfizerpro.com/hcp/prevnar13-adult

 

I have no financial interests in Prevnar or Pneumovax.

 

Seto

South Pasadena, CA